Lung Cancer CALGB 30607

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progesssing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.

Connect With Us

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.

Hartford HealthCare Offices

One State Street, Suite 19, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.